Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells

@article{Marzo2004FarnesyltransferaseIB,
  title={Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells},
  author={Isabel Bayona Marzo and Patricia P{\'e}rez-Gal{\'a}n and Pilar Giraldo and Nuria L{\'o}pez-Royuela and Mar{\'i}a Jos{\'e} G{\'o}mez-Benito and Luis Larrad and P. Albert Lasierra and Daniel Rubi{\'o}-F{\'e}lix and Alberto Anel and Javier Naval},
  journal={Leukemia},
  year={2004},
  volume={18},
  pages={1599-1604}
}
B-cell chronic lymphocytic leukemia (B-CLL) cells develop resistance to nucleoside analogs over time. This chemoresistance may be caused by selection for B-CLL cells with defects in the particular apoptosis pathway triggered by these drugs. Therefore, anticancer agents that induce apoptosis through alternative pathways might be useful in treating chemoresistant B-CLL. Farnesyltransferase inhibitors (FTIs) are a class of synthetic drugs with definite molecular targets, which have demonstrated… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

BMS-214662 (Bristol-Myers Squibb).

  • IDrugs : the investigational drugs journal
  • 2003